News

Five months have flashed past since the CBI's risk-based monitoring event, and so I was looking forward to observing how much the industry has moved on.

Sites: Making a Difference in Cancer Trials Accrual Trial Design: Oncology Trial Comparator Drug Reimbursement Also in this issue: Singular Approach to Combination Trials Risk Sharing and Interrupted Drug Development Cardio-Oncology: A New Clinical Discipline

With the European Union's new rules on clinical trials?including data access?approaching their final legislative stage, and the European Medicines Agency planning to announce its new rules on data disclosure within weeks, the European drug industry is still running to catch up with transparency issues.